USPTO 2015–2025 USPTO PatentsView US Corporation

Iovance Biotherapeutics, Inc.

USPTO PatentsView assignee record — 92 granted patents across 9 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

92
Total patents granted
9
CPC technology areas
22.0
Avg claims per patent
+822%
5-year filing velocity

Portfolio overview

Iovance Biotherapeutics, Inc. has been granted 92 US utility patents between 2018 and 2025, placing Iovance Biotherapeutics, Inc. at rank #3,924 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.0 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Iovance Biotherapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 48.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 83 grants, compared with 9 in the 2015–2019 window — a +822% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Iovance Biotherapeutics, Inc.'s 22.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Iovance Biotherapeutics, Inc. against peers pursuing similar technology classes.

How does Iovance compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Iovance holds 92 patents — placing it at rank #3,924 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2018–2025

-100102030 20182019202020212022202320242025 8
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Iovance Biotherapeutics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 1 1.1%
2019 8 8.7%
2020 5 5.4%
2021 23 25.0%
2022 26 28.3%
2023 6 6.5%
2024 15 16.3%
2025 8 8.7%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#3,924

Across all tracked assignees

Innovation Score

48.2 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Iovance Biotherapeutics, Inc. hold?
Iovance Biotherapeutics, Inc. holds 92 US granted patents filed between 2018 and 2025, spanning 9 technology areas.
What is Iovance Biotherapeutics, Inc.'s Innovation Score?
Iovance Biotherapeutics, Inc. has an Innovation Score of 48.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Iovance Biotherapeutics, Inc. focus on?
Iovance Biotherapeutics, Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 91 patents. The company has filed patents in 9 CPC subclasses total.
Is Iovance Biotherapeutics, Inc.'s patent filing rate increasing or decreasing?
Iovance Biotherapeutics, Inc.'s recent filing velocity is +822% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Iovance Biotherapeutics, Inc.'s patents?
Iovance Biotherapeutics, Inc.'s patents average 22.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Iovance Biotherapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope